Latest Strategy News

Pro Medicus Limited’s U.S. arm has secured a significant five-year, A$44 million contract to deploy its cloud-based Visage 7 imaging platform with Advanced Radiology Management, marking a strategic expansion in North America.

Locksley Resources has partnered with Columbia University to develop cutting-edge, sustainable technologies for rare earth and critical mineral processing in the US, advancing its Mine-to-Market strategy amid growing government support.

Patriot Resources reports significant copper-zinc-lead assay results from its Phase 1 trenching at Kitumba, Zambia, expanding the mineralised footprint fivefold and setting the stage for further exploration.

Island Pharmaceuticals has secured FDA confirmation that its antiviral Galidesivir can proceed under the Animal Rule pathway for Marburg virus, qualifying for a lucrative Priority Review Voucher. This regulatory milestone accelerates the drug’s path to approval and potential government stockpile inclusion.

Nexion Group has finalized the sale of its Nexion Networks and Blue Sky Telecom subsidiaries, pivoting its focus towards AI-driven business intelligence through Fuse Forward.

Spacetalk launches its subscription-based Freedom Platform, aiming to transform family safety tech and hit $20-25 million in annual recurring revenue by 2026. The new app connects multiple generations, expanding beyond smartwatches into a broader digital ecosystem.

Cann Group Limited reminds eligible shareholders that its Share Purchase Plan (SPP) closes today, offering new shares at a discount plus free attaching options, pending shareholder approval.

Diablo Resources has appointed Matthew Blumberg as a Non-Executive Director and brought on Ellis Martin as its U.S. Media and Investor Communications Advisor, signaling a strategic push into North American markets.

Algorae Pharmaceuticals has launched a Loyalty Options Offer, allowing eligible shareholders to purchase options at a nominal price, aiming to reward loyalty and support future growth funding.

HMC Capital has secured an increased and extended revolving debt facility, enhancing its underwriting capacity and supporting strategic growth initiatives, including its energy transition efforts.

Algorae Pharmaceuticals has announced a non-renounceable Loyalty Options Offer to eligible shareholders, aiming to raise up to $337,678 before costs, with potential additional capital of $4.7 million if all options are exercised. The capital raise supports the company’s pharmaceutical and AI research and development ambitions.

Race Oncology has announced pivotal new clinical trials for its lead asset RC220, aiming to accelerate regulatory approval in Acute Myeloid Leukemia and tackle resistance in Non-Small Cell Lung Cancer.